Clinical Trial Detail

NCT ID NCT03304639
Title Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.